OR
Oryzon Genomics S.A.
ORYZF · OTC
$3.31 +0.00% (+$0.00)
1M +1.22%
Market Cap 238.5M €
P/E Ratio -
Div. Yield -
ROE 2.16%
Bulios Fair Price
$2.97
10.3% downside
Current Price
$3.31
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ORYZF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
44 /100
Fair P/B 1.99x
P/S 27.43x
EV/EBITDA N/A
Growth
96 /100
Growing Book val. growth 13.25%
Rev. growth N/A
FCF growth N/A
Profitability
22 /100
Weak Net margin 27.11%
Op. margin 72.84%
FCF margin 0.00%
Quality
1 /100
Poor ROE 2.16%
ROA 1.68%
Asset turnover 0.06x
Debt
65 /100
Moderate Current ratio 1.60x
Int. coverage -14.46x
Debt/Equity 0.05x
Stability
42 /100
Moderate Rev. volatility 45.36%
EPS volatility 21.14%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ORYZF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Carlos Manuel Buesa Arjol
Employees
46
Headquarters
Cornellà de Llobregat
Upcoming events
06 NOV
Earnings
Upcoming earnings report